News >

Stratification Schemes Guide Treatment Decisions in MCL

Caroline Seymour
Published: Monday, Mar 18, 2019

Andre Goy, MD

Andre Goy, MD
Deciding which therapy to pursue for a patient with mantle cell lymphoma (MCL) is dependent on 3 criteria, explained Andre Goy, MD, MS. Specifically, whether a patient’s disease is indolent or symptomatic, their age and fitness, and the presence of certain high-grade molecular markers.

, Goy, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, shared further insight on the stratification of patients with MCL and other molecular markers that are being applied towards optimal treatment decisions in this disease.

OncLive: Could you discuss the treatment options for patients with MCL?

Goy: Approximately 5% to 15% of patients have indolent disease. These are asymptomatic patients who have a high white count, splenomegaly, and minimal lymphadenopathy, if any. These patients can be monitored over time. Sometimes, these patients can acquire a p53 abnormality, [in which the disease] can transform aggressively. It's rare, but it can happen. These patients can be monitored and not treated early on.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x